Immunotherapy outcomes in non-small cell lung cancer according to a gender perspective. in Progress in molecular biology and translational science / Prog Mol Biol Transl Sci. 2024;209:241-258. doi: 10.1016/bs.pmbts.2024.09.004. Epub 2024 Oct 11.
2024
AOU Città della Salute di Torino
Tipo pubblicazione
Review
Autori/Collaboratori (1)
Vavalà T
AOU Città della Salute e della Scienza-Dipartimento di Oncologia, SC Oncologia 1U, Torino, Italy. Electronic address: tvavala@gmail.com.
Abstract
In the last few years, immune checkpoint inhibitors (ICIs) improved treatment strategies for advanced non-small cell lung cancer (NSCLC) with no targetable driver mutations. Empirical evidence strongly suggests that males and females differ in outcomes following the use of ICIs for treatments of solid cancers. Women in fact exhibit greater humoral and cell-mediated immune responses and an even more advanced immune editing which plays an important role in controlling cancer rising and evolution. However, at present, no conclusive studies have addressed differences in response to ICIs regarding sex and, to note, reproductive status in women or autoimmune diseases in both sexes are often not recorded in clinical trials. Consequently, it can be argued that to assess cancer responses and study cancer spread, results of published studies in men may not unconditionally be applied on female patients treated with ICIs, and vice versa. In this chapter have been discussed recent data about gender differences in the immune system and in NSCLC patients treated with ICIs, highlighting sex as a key factor in evaluating different responses in the two sexes.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 39461754
DOI : 10.1016/bs.pmbts.2024.09.004
Keywords
Humans; Carcinoma, Non-Small-Cell Lung/immunology/pathology/drug therapy/therapy/genetics; Lung Neoplasms/immunology/drug therapy/pathology/therapy/genetics; Immunotherapy; Female; Male; Treatment Outcome; Sex Characteristics; Immune Checkpoint Inhibitors/therapeutic use; Sex Factors; CTLA-4; Gender approach; Immune checkpoint inhibitors; Immunotherapy; Lung cancer; NSCLC; PD-1; PD-L1; Sex differences; Women;